Anti-Cancer antibodies:

The recent clinical and commercial
success of anticancer antibodies such
as Rituxan and Herceptin has created
great interest in antibody based
therapeutics for hematopoietic
malignant neoplasms and solid tumors.
Given the likelihood of lower toxic
effects of antibodies that target tumor
cells and have limited impact on
nonmalignant bystander organs vs
small molecules, the potential
increased efficacy  and the ability to
characterize the target with clinical
laboratory diagnostics to improve the
drug’s clinical performance, current
and future antibody therapeutics are
likely to find substantial roles alone
and in combination therapeutic
strategies.

CURRENT ANTICANCER ANTIBODIES
IN PHASE 3 CLINICAL TRIALS
Brand
Maker
What for

Tositumomab (Bexxar)
Corixa, Seattle, WA
Anti-CD20 murine monoclonal antibody
with iodine 131 conjugation

CeaVac
Titan Pharmaceuticals, South San
Francisco, CA
Anti-CEA murine monoclonal antibody;
anticancer immunologic  vaccine

Epratuzumab (LymphoCide)
Immunomedics, Morris Plains, NJ
Chimeric monoclonal antibody;
anticancer immunologic;
immunosuppressant

Mitumomab
ImClone Systems, New York, NY
Murine monoclonal antibody;
anticancer immunologic

Bevacizumab (Avastin)
Genentech, South San Francisco, CA
Anti-VEGF humanized monoclonal
antibody; anticancer immunologic;
antidiabetic; ophthalmologic

Cetuximab (C-225; Erbitux)
ImClone Systems
Anti-EGFR chimeric monoclonal
antibody; anticancer immunologic

Edrecolomab
Johnson & Johnson, New Brunswick, NJ
Murine monoclonal antibody;
anticancer immunologic

Lintuzumab (Zamyl)
Protein Design Labs, Fremont, CA
Chimeric monoclonal antibody;
anticancer immunologic

MDX-210
Medarex, Princeton, NJ; Immuno-  
antibody; anti–HER-2/neu–anti-Fc
Bispecific chimeric monoclonal
antibody; anti–HER-2/neu–anti-Fc
gamma RI; anticancer immunologic

IGN-101
Igeneon, Vienna, Austria
Murine monoclonal antibody;
anticancer immunologic

DRUGS
Current blockbuster drugs: Roche and
Genentech’s Herceptin, Genentech's
Avastin;

Potential blockbusters: Bristol-Myers
Squibb via its recently acquired
ImClone Systems and its IMC-1121b,
in  Phase 3 trials;